Xconomy

OCTOBER 24, 2018

Amgen is cutting the list price of its new cholesterol-lowering drug by nearly 60 percent, a move the company says is intended to make the product more affordable for more patients. The Tarrytown, NY firm recently offered significant price cuts to insurance companies that help boost access to its rival medicine alirocumab (Praluent).

Pricing 55

Pricing Help Product San Diego 55

Xconomy

JANUARY 29, 2019

closing price on Monday. In return, San Diego-based Neurocrine will gain rights to Voyager’s. Neurocrine (NASDAQ: NBIX ) has agreed to pay Voyager (NASDAQ: VYGR ) $115 million in cash and buy $50 million worth of the Cambridge, MA, company’s shares at $11.96 apiece—a roughly 50 percent premium to its $8.04

San Diego 108

San Diego Pricing Product Company 108

Xconomy

JULY 8, 2020

Dave Johnson has known UC San Diego physician and cancer reseacher Thomas Kipps for nearly 20 years.

San Diego 121

San Diego Develop Development UCSD 121

Xconomy

MARCH 10, 2018

And in an unusual move, Regeneron—based on input from the nonprofit drug-pricing watchdog, the Institute for Clinical and Economic Review (ICER)—vows to cut the cost of the drug if it can get certain concessions from insurers. Regeneron and Amgen, which makes a competing drug, have struggled mightily to get payers to cover.

Pricing 82

Pricing Report San Diego Blogging 82

Xconomy

AUGUST 2, 2019

Investors, however, buoyed the company’s share price this week after Acadia (NASDAQ: ACAD ) announced it anticipated that sales of Nuplazid, its sole commercial drug, Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 61

Pricing Sales Company Companies 61

Xconomy

JANUARY 10, 2020

Signatories agreed to what they dubbed a New Commitment to Patients, a list of “core principals and actions” promising that “pricing of our medicines at launch will reflect innovation and value to patients” and “any price increases on our medicines must be reasonable and guided by the need for uninterrupted patient access.”

Pricing 52

Pricing Guide San Diego Company 52

Xconomy

JULY 2, 2018

A paper published last week in the journal JAMA Oncology makes the case that one such test, Oncotype DX AR-V7 Nucleus Detect, might be worth its $3,980 price tag. Earlier this year, the federal insurance program Medicare sent positive signals about coverage but hasn’t made a final decision.)

Guide 81

Guide Study San Diego Journal 81

Xconomy

DECEMBER 28, 2016

But as expected, the drug, from Biogen and Ionis Pharmaceuticals, is a costly one, priced at the high end of the six figure price tags often given to treatments for rare diseases with no alternative treatments. The per-injection price translates into $750,000 for.

Pricing 63

Pricing News Marketing San Diego 63

Xconomy

APRIL 17, 2019

Turning Point Therapeutics raised more than $166 million in its IPO, pricing at the top of its range and putting nearly 2 million more shares into the public markets than it had initially planned. million shares at $18 apiece, raising $166.5 million before discounts, commissions, and offering expenses.

Pricing 57

Pricing Demand Marketing Develop 57

Xconomy

NOVEMBER 19, 2018

The San Diego-based biotech set a preliminary $100 million target for its IPO in documents filed with securities regulators Friday. That figure will change as the company determines how many shares it will sell and at what price. Cibus has applied for a listing on the Nasdaq exchange under the stock symbol “CBUS.”

San Diego 72

San Diego Research Startup Pricing 72

Xconomy

APRIL 26, 2019

The road to every new drug approval is littered with the remains of earlier failures. Biopharmaceutical companies don’t like to talk about the failures. But it’s earnings season now, so some of them don’t have much choice.

News 94

News Pricing Study Company 94

Xconomy

JULY 14, 2017

Akcea Therapeutics is joining the parade of biotechs going public, but the company had to cut its stock price and sell more shares in order to pull it off. But the biotech priced its offering of 15.6 Cambridge, MA-based Akcea had planned on raising $125 million from the initial public offering, and it hit that target.

Pricing 57

Pricing Company Companies San Diego 57

Xconomy

APRIL 13, 2017

San Diego-based Tocagen (NASDAQ: TOCA ) priced its offering of 8.5 million shares priced between $10 to $12 each. Tocagen raised $85 million in its stock market debut today, and underwriters saw enough demand to increase the number of shares in the initial public offering. million shares at $10 per share.

San Diego 66

San Diego Pricing Demand Marketing 66

Xconomy

FEBRUARY 4, 2019

Battery-technology business Maxwell Technologies has agreed to be acquired by Silicon Valley electric car company Tesla (NASDAQ: TSLA ) in an all-stock deal valued at about $218 million, the San Diego-based company announced Monday. apiece, a 55 percent premium over its stock price as of market close Feb.

Technology 46

Technology San Diego Pricing News 46

Xconomy

DECEMBER 10, 2018

ASG Technologies, the Florida-based software company backed by activist hedge fund Elliott Management, has upped its offer for San Diego’s Mitek Systems to $11.50 The stock price of Mitek (NASDAQ:MITK) rose nearly 9 percent on the news, closing at $9.75. per share from $10 apiece. That’s according to a Nov.

Pricing 43

Pricing Acquisition News Software 43

Xconomy

MARCH 10, 2017

The San Diego-based biotech filed the paperwork Thursday for an IPO that could raise up to $86 million—a figure likely to change as the company determines how many shares it will sell, and at what price. Tocagen has applied to the Nasdaq Exchange for a listing under the stock symbol “TOCA.”

San Diego 79

San Diego Pricing Southern California Develop 79

Xconomy

JULY 29, 2020

On Wednesday the Cambridge, MA-based company, which was launched last year by Third Rock Ventures, announced that New York investment firm Casdin Capital and San Diego area-based venture firm Section 32 had co-led its Series B. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

San Diego 87

San Diego Study Capital Invest 87

Xconomy

DECEMBER 18, 2018

The venture investment, which the San Diego startup announced Tuesday, is one of only a few so-called mega-rounds—$100 million or more—recorded this year in the region. (In Thompson to its board of directors. In Southern California, rounds that large are more often raised by life sciences companies.)

Southern California 110

Southern California San Diego Software Invest 110

Xconomy

FEBRUARY 2, 2018

The San Diego-based early stage biotech, which specializes in RNA medicines, did not explain in a statement today why the Arcturus board decided to terminate Payne—only that his dismissal “is not related to Arcturus’ operational performance, ongoing programs, financial condition, or financial reporting.”

Arcturus 56

Arcturus San Diego Pricing Report 56

Xconomy

AUGUST 25, 2017

This week saw some skirmishes in the drug price debate, new plans to expand the. Those of us who stepped outside with eclipse glasses, pin-hole projectors, or even colanders found a brief respite from the news. But developments in health policy and life sciences march onward. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 49

Pricing News Develop Development 49

Xconomy

MARCH 12, 2018

For 20 years, Deborah Long (pictured) has been relying on powerful drugs to keep her multiple sclerosis in check. Her out-of-pocket costs were pretty reasonable until two years ago, she says, when she had to switch insurance companies. Her new insurer made her switch to a different drug, Copaxone.

Pricing 71

Pricing San Diego Company Companies 71

Xconomy

SEPTEMBER 13, 2019

For decades, advanced lung cancer was a quick death sentence. That’s no longer a given, thanks in part to the arrival of immunotherapy. If a medical meeting in Barcelona this week was any indication, more help could be on the way.

Pricing 63

Pricing Help San Diego Avalon 63

Xconomy

APRIL 23, 2019

As public backlash against high drug prices shows no signs of waning, a private nonprofit in Boston, the Institute for Clinical Economic Review (ICER), has emerged as the country’s top drug-pricing watchdog. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 104

Pricing Report Funding San Diego 104

Xconomy

AUGUST 15, 2019

Now the corporate venture arm of the global package delivery giant says it has taken a minority stake in the San Diego startup, which believes its technology can reduce the costs of shipping goods via tractor-trailer by 30 percent. Financial terms of the deal, announced Thursday, weren’t disclosed.

San Diego 79

San Diego Startup Technology Company 79

Xconomy

DECEMBER 21, 2018

It’s beginning to look a lot like, well, the last roundup of the year, with plenty of news to pack in before our holiday breather.

Pricing 73

Pricing Sales Study News 73

Xconomy

NOVEMBER 26, 2019

La Jolla Pharmaceutical is turning its focus to its lone FDA-approved product and another one in the pipeline after an experimental drug for a rare blood disease failed a late-stage study.

Pricing 63

Pricing Study Product San Diego 63

Xconomy

AUGUST 30, 2017

Ahead of schedule, Novartis has received the first-ever approval of a genetically modified living cell therapy called CAR-T, which uses a cancer patient’s own immune cells as the medicine.

Pricing 81

Pricing Conference San Diego Research 81

Xconomy

JUNE 16, 2016

In San Diego, the complaints often focus on the relative scarcity of venture capital and hometown VC firms. So when the San Diego Venture Group recruited Mark Suster of Los Angeles-based Upfront Ventures to give the keynote talk Tuesday night for Startup Week San Diego, more than 800 people filled a downtown auditorium.

Venture Capital 49

Venture Capital San Diego Truecar Web 49

Xconomy

JANUARY 31, 2020

million more shares than anticipated and pricing at the high end of its planned range. The stock price closed at $21.80, up 28 percent. Arcutis Biotherapeutics raised about $159 million from its IPO, offering 1.6 The Westlake Village, CA-based biotech sold about 9.4 million of its shares at $17 apiece.

Westlake Village 114

Westlake Village Pricing Develop Development 114

Xconomy

OCTOBER 27, 2016

Prices for agricultural commodities such as corn, soy, and wheat are at their lowest levels in years, but investment in agricultural technology has never been better. The increase in dollars flowing to agtech comes despite commodity prices that are down 65 percent from their 2013 peak, the report says. They also queried 15 VC firms.

Venture Capital 40

Venture Capital Pricing Invest Report 40

Xconomy

MAY 16, 2018

For some migraine sufferers, bright lights or loud sounds are enough to touch off an attack. For others, stress sparks the onset of pain. Bright lights, loud sounds, stress: Migraine triggers vary from one patient to another. But a common element is the abundance of a pain-inducing protein in the blood.

Pricing 77

Pricing Develop Development San Diego 77

Xconomy

OCTOBER 6, 2016

Headed by the computational neuroscientist Eugene Izhikevich, the company maintained a low profile at Qualcomm’s San Diego headquarters until 2013, when Brain Corp. The company actually has been test-driving its technology on floor scrubbers used to clean Jimbo’s, a San Diego natural foods grocer. “We While Brain Corp.

Product 106

Product Artificial Inteligence San Diego Training 106

Xconomy

OCTOBER 13, 2016

Qualcomm (NASDAQ: QCOM ), the San Diego wireless technology giant, announced in a blog item this week that its Halo wireless electric vehicle charging technology will be available commercially for the first time in 2017, with the mid-year introduction of the 2018 model of the Mercedes-Benz S550e.

San Diego 40

San Diego Blogging Pricing Technology 40

Xconomy

FEBRUARY 27, 2017

La Jolla Pharmaceutical’s experimental drug to treat a deadly blood pressure condition hit its main goal in a Phase 3 clinical trial, boosting the company’s stock price by more than 75 percent on Monday morning.

San Diego 40

San Diego Study Pricing Organization 40

Xconomy

AUGUST 31, 2020

That price is a 60 percent premium to the Boston-based company’s closing stock price on Friday. The definitive agreement announced Monday calls for Carlsbad, CA-based Ionis (NASDAQ: IONS ) to pay $18.15 for each share of Akcea (NASDAQ: AKCA ) that it does not already own. Akcea develops drugs for rare diseases.

Pricing 89

Pricing Product Develop Development 89

Xconomy

FEBRUARY 21, 2020

The price of insulin, a life-saving treatment discovered a century ago, has been a flashpoint amid the broader drug pricing debate. The FDA is trying to tame high insulin prices by encouraging price competition. The FDA has historically regarded insulin as a drug.

Pricing 79

Pricing Competition Product Marketing 79

Xconomy

DECEMBER 20, 2016

San Diego-based Acadia (NASDAQ: ACAD ) reported that patients treated in an exploratory study with its drug pimavanserin showed a statistically significant reduction in psychosis compared against a group given a placebo. Investors cheered the news, boosting Acadia’s stock price 13.6 percent to $28.88

San Diego 40

San Diego Statistics Study News 40